Clinical Trials
38 trialsNCT04514484 2026-05-28
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03797326 2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04225117 2026-04-13
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT04332653 2026-03-09
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Phase 1/2 Completed
NCT05001347 2025-12-16
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
Phase 2 Completed
NCT04504916 2025-11-10
MK-2140-002
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Terminated
NCT03620643 2025-10-30
ROLo
Royal Marsden NHS Foundation Trust
Phase 2 Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT04577963 2025-07-14
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT04442126 2025-05-23
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
Phase 1/2 Terminated
NCT03829501 2025-04-02
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
Phase 1/2 Terminated
NCT03154190 2025-01-24
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
Phase NA Completed
NCT03150810 2024-12-20
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
BeiGene
Phase 1 Completed
NCT03761914 2024-11-19
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
Phase 1/2 Completed
NCT03345485 2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2 Completed
NCT03207867 2024-10-09
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis
Phase 2 Terminated
NCT03251378 2024-09-25
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
Hutchmed
Phase 1 Completed
NCT02554812 2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2 Terminated
NCT03621982 2024-06-13
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
Phase 1 Terminated
NCT03256344 2024-05-14
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Amgen
Phase 1 Completed
NCT04148937 2024-04-05
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03576131 2023-08-01
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
Genmab
Phase 1/2 Terminated
NCT04424641 2023-07-25
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Genmab
Phase 1/2 Terminated
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT03435640 2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2 Terminated
NCT02762981 2022-12-06
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
Corcept Therapeutics
Phase 1/2 Completed
NCT03241173 2022-09-27
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03875313 2022-02-17
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Calithera Biosciences, Inc
Phase 1/2 Terminated
NCT02178722 2022-02-14
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
Phase 1/2 Completed
NCT04099277 2021-08-31
A Study of LY3435151 in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT01631552 2021-08-12
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
Phase 1/2 Completed
NCT02807844 2021-08-11
Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Novartis
Phase 1/2 Completed
NCT03098550 2021-07-23
A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03277352 2021-07-22
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02659631 2020-05-06
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT01770353 2019-11-27
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Ipsen
Phase 1 Completed
NCT01451632 2016-09-08
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Merrimack Pharmaceuticals
Phase 1 Completed